Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-term Extension of a Phase 2, Open-Label Dose-Finding Study to Evaluate the Safety, Efficacy, and Tolerability of Multiple Subcutaneous Doses of rAvPAL-PEG in Subjects With PKU

Trial Profile

Long-term Extension of a Phase 2, Open-Label Dose-Finding Study to Evaluate the Safety, Efficacy, and Tolerability of Multiple Subcutaneous Doses of rAvPAL-PEG in Subjects With PKU

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2018

At a glance

  • Drugs Pegvaliase (Primary)
  • Indications Phenylketonuria
  • Focus Therapeutic Use
  • Sponsors BioMarin Pharmaceutical
  • Most Recent Events

    • 07 Nov 2018 Results presented in a BioMarin Pharmaceutical media release.
    • 18 Jul 2018 Results from (NCT00634660, NCT01560286, NCT00925054, NCT01212744, NCT00924703, NCT01819727 and NCT01889862) published in the BioDrugs
    • 05 Sep 2017 According to a BioMarin Pharmaceutical media release, data will be presented at the 13th International Congress of Inborn Errors of Metabolism (ICIEM) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top